STOCK TITAN

[Form 4] Apogee Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Andrew Gottesdiener, Director at Apogee Therapeutics, received a stock option grant to purchase 14,461 shares of common stock at an exercise price of $41.66 per share on June 17, 2025.

Key details of the option grant:

  • Exercise price: $41.66 per share
  • Vesting: 100% on one-year anniversary of grant date
  • Expiration date: June 17, 2035
  • Subject to continued service with the company

Notable arrangement: The options are held under an agreement with VR Management, LLC, where Gottesdiener must exercise the options solely at their direction. VR Management is entitled to the underlying shares, with Gottesdiener disclaiming beneficial ownership except for his pecuniary interest.

Andrew Gottesdiener, direttore presso Apogee Therapeutics, ha ricevuto un'opzione su azioni per acquistare 14.461 azioni ordinarie a un prezzo di esercizio di 41,66 $ per azione il 17 giugno 2025.

Dettagli principali dell'opzione:

  • Prezzo di esercizio: 41,66 $ per azione
  • Vesting: 100% al primo anniversario della data di concessione
  • Data di scadenza: 17 giugno 2035
  • Condizionato alla continua collaborazione con l'azienda

Accordo rilevante: Le opzioni sono detenute in base a un accordo con VR Management, LLC, per cui Gottesdiener deve esercitare le opzioni esclusivamente secondo le loro indicazioni. VR Management ha diritto alle azioni sottostanti, mentre Gottesdiener rinuncia alla proprietà beneficiaria salvo il suo interesse pecuniario.

Andrew Gottesdiener, director en Apogee Therapeutics, recibió una opción sobre acciones para comprar 14,461 acciones ordinarias a un precio de ejercicio de $41.66 por acción el 17 de junio de 2025.

Detalles clave de la concesión de la opción:

  • Precio de ejercicio: $41.66 por acción
  • Consolidación: 100% en el primer aniversario de la fecha de concesión
  • Fecha de vencimiento: 17 de junio de 2035
  • Sujeto a la continuidad del servicio en la empresa

Acuerdo notable: Las opciones están bajo un acuerdo con VR Management, LLC, donde Gottesdiener debe ejercer las opciones únicamente bajo su dirección. VR Management tiene derecho a las acciones subyacentes, y Gottesdiener renuncia a la propiedad beneficiaria excepto por su interés pecuniario.

Andrew GottesdienerApogee Therapeutics의 이사로서 2025년 6월 17일에 주당 41.66달러의 행사가격으로 14,461주의 보통주를 매수할 수 있는 스톡옵션을 부여받았습니다.

옵션 부여의 주요 내용:

  • 행사가격: 주당 41.66달러
  • 베스팅: 부여일로부터 1년 후 100%
  • 만료일: 2035년 6월 17일
  • 회사의 지속적인 근무 조건

특이사항: 이 옵션은 VR Management, LLC와의 계약 하에 보유되며, Gottesdiener는 VR Management의 지시에 따라서만 옵션을 행사해야 합니다. VR Management가 기초 주식에 대한 권리를 가지며, Gottesdiener는 금전적 이익을 제외한 실질적 소유권을 포기합니다.

Andrew Gottesdiener, directeur chez Apogee Therapeutics, a reçu une attribution d'options d'achat portant sur 14 461 actions ordinaires au prix d'exercice de 41,66 $ par action, en date du 17 juin 2025.

Détails clés de l'attribution des options :

  • Prix d'exercice : 41,66 $ par action
  • Acquisition : 100 % à la date anniversaire d'un an de l'attribution
  • Date d'expiration : 17 juin 2035
  • Sous réserve de la poursuite de son service au sein de l'entreprise

Disposition notable : Les options sont détenues dans le cadre d'un accord avec VR Management, LLC, selon lequel Gottesdiener doit exercer les options uniquement sous leur direction. VR Management a droit aux actions sous-jacentes, Gottesdiener renonçant à la propriété bénéficiaire sauf pour son intérêt pécuniaire.

Andrew Gottesdiener, Direktor bei Apogee Therapeutics, erhielt am 17. Juni 2025 eine Aktienoptionszusage zum Kauf von 14.461 Stammaktien zu einem Ausübungspreis von 41,66 $ pro Aktie.

Wichtige Details der Optionszusage:

  • Ausübungspreis: 41,66 $ pro Aktie
  • Vesting: 100 % am einjährigen Jahrestag der Gewährungsdatum
  • Ablaufdatum: 17. Juni 2035
  • Vorbehaltlich der fortgesetzten Tätigkeit im Unternehmen

Besondere Vereinbarung: Die Optionen werden im Rahmen einer Vereinbarung mit VR Management, LLC gehalten, wobei Gottesdiener die Optionen ausschließlich nach deren Anweisung ausüben muss. VR Management ist berechtigt, die zugrundeliegenden Aktien zu erhalten, während Gottesdiener das wirtschaftliche Eigentum mit Ausnahme seines finanziellen Interesses ablehnt.

Positive
  • None.
Negative
  • None.

Andrew Gottesdiener, direttore presso Apogee Therapeutics, ha ricevuto un'opzione su azioni per acquistare 14.461 azioni ordinarie a un prezzo di esercizio di 41,66 $ per azione il 17 giugno 2025.

Dettagli principali dell'opzione:

  • Prezzo di esercizio: 41,66 $ per azione
  • Vesting: 100% al primo anniversario della data di concessione
  • Data di scadenza: 17 giugno 2035
  • Condizionato alla continua collaborazione con l'azienda

Accordo rilevante: Le opzioni sono detenute in base a un accordo con VR Management, LLC, per cui Gottesdiener deve esercitare le opzioni esclusivamente secondo le loro indicazioni. VR Management ha diritto alle azioni sottostanti, mentre Gottesdiener rinuncia alla proprietà beneficiaria salvo il suo interesse pecuniario.

Andrew Gottesdiener, director en Apogee Therapeutics, recibió una opción sobre acciones para comprar 14,461 acciones ordinarias a un precio de ejercicio de $41.66 por acción el 17 de junio de 2025.

Detalles clave de la concesión de la opción:

  • Precio de ejercicio: $41.66 por acción
  • Consolidación: 100% en el primer aniversario de la fecha de concesión
  • Fecha de vencimiento: 17 de junio de 2035
  • Sujeto a la continuidad del servicio en la empresa

Acuerdo notable: Las opciones están bajo un acuerdo con VR Management, LLC, donde Gottesdiener debe ejercer las opciones únicamente bajo su dirección. VR Management tiene derecho a las acciones subyacentes, y Gottesdiener renuncia a la propiedad beneficiaria excepto por su interés pecuniario.

Andrew GottesdienerApogee Therapeutics의 이사로서 2025년 6월 17일에 주당 41.66달러의 행사가격으로 14,461주의 보통주를 매수할 수 있는 스톡옵션을 부여받았습니다.

옵션 부여의 주요 내용:

  • 행사가격: 주당 41.66달러
  • 베스팅: 부여일로부터 1년 후 100%
  • 만료일: 2035년 6월 17일
  • 회사의 지속적인 근무 조건

특이사항: 이 옵션은 VR Management, LLC와의 계약 하에 보유되며, Gottesdiener는 VR Management의 지시에 따라서만 옵션을 행사해야 합니다. VR Management가 기초 주식에 대한 권리를 가지며, Gottesdiener는 금전적 이익을 제외한 실질적 소유권을 포기합니다.

Andrew Gottesdiener, directeur chez Apogee Therapeutics, a reçu une attribution d'options d'achat portant sur 14 461 actions ordinaires au prix d'exercice de 41,66 $ par action, en date du 17 juin 2025.

Détails clés de l'attribution des options :

  • Prix d'exercice : 41,66 $ par action
  • Acquisition : 100 % à la date anniversaire d'un an de l'attribution
  • Date d'expiration : 17 juin 2035
  • Sous réserve de la poursuite de son service au sein de l'entreprise

Disposition notable : Les options sont détenues dans le cadre d'un accord avec VR Management, LLC, selon lequel Gottesdiener doit exercer les options uniquement sous leur direction. VR Management a droit aux actions sous-jacentes, Gottesdiener renonçant à la propriété bénéficiaire sauf pour son intérêt pécuniaire.

Andrew Gottesdiener, Direktor bei Apogee Therapeutics, erhielt am 17. Juni 2025 eine Aktienoptionszusage zum Kauf von 14.461 Stammaktien zu einem Ausübungspreis von 41,66 $ pro Aktie.

Wichtige Details der Optionszusage:

  • Ausübungspreis: 41,66 $ pro Aktie
  • Vesting: 100 % am einjährigen Jahrestag der Gewährungsdatum
  • Ablaufdatum: 17. Juni 2035
  • Vorbehaltlich der fortgesetzten Tätigkeit im Unternehmen

Besondere Vereinbarung: Die Optionen werden im Rahmen einer Vereinbarung mit VR Management, LLC gehalten, wobei Gottesdiener die Optionen ausschließlich nach deren Anweisung ausüben muss. VR Management ist berechtigt, die zugrundeliegenden Aktien zu erhalten, während Gottesdiener das wirtschaftliche Eigentum mit Ausnahme seines finanziellen Interesses ablehnt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gottesdiener Andrew

(Last) (First) (Middle)
C/O APOGEE THERAPEUTICS, INC.
221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)
WALTHAM MA 02453

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $41.66 06/17/2025 A 14,461 (1) 06/17/2035 Common Stock 14,461 $0.00 14,461 D(2)
Explanation of Responses:
1. This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.
2. Under an agreement between the Reporting Person and VR Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.
/s/ Matthew Batters, as attorney-in-fact for Andrew Gottesdiener 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did APGE director Andrew Gottesdiener receive on June 17, 2025?

Andrew Gottesdiener received stock options to purchase 14,461 shares of APGE common stock at an exercise price of $41.66 per share. The options will vest on the one-year anniversary of the grant date (June 17, 2026), subject to his continued service with the company.

When do Andrew Gottesdiener's APGE stock options expire?

The stock options granted to Andrew Gottesdiener expire on June 17, 2035, which is 10 years from the grant date.

What is the special arrangement between APGE director Gottesdiener and VR Management regarding his stock options?

Under an agreement with VR Management, LLC, Gottesdiener holds the options for the sole benefit of the Management Company and must exercise them only upon their direction. VR Management is entitled to the underlying shares and may be deemed the indirect beneficial owner, while Gottesdiener disclaims beneficial ownership except for his pecuniary interest.

What is the exercise price of APGE stock options granted to director Gottesdiener in June 2025?

The stock options were granted with an exercise price of $41.66 per share.
Apogee Therapeutics Inc

NASDAQ:APGE

APGE Rankings

APGE Latest News

APGE Latest SEC Filings

APGE Stock Data

2.55B
41.42M
11.37%
130.16%
13.36%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WALTHAM